Thus, the inhibition by MASTL of drug-induced cell death may not only account for failure of standard chemotherapy, but may also help explain why MASTL overexpression contributes to the malignant phenotype of colon cancer. The gene discussed is MASTL; the disease is malignant colon neoplasm.